Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19)

AR Bourgonje, AE Abdulle, W Timens… - The Journal of …, 2020 - Wiley Online Library
Abstract Angiotensin‐converting enzyme 2 (ACE2) has been established as the functional
host receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus …

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2

M Gheblawi, K Wang, A Viveiros, Q Nguyen… - Circulation …, 2020 - Am Heart Assoc
ACE2 (angiotensin-converting enzyme 2) has a multiplicity of physiological roles that
revolve around its trivalent function: a negative regulator of the renin-angiotensin system …

COVID-19: Immunology and treatment options

S Felsenstein, JA Herbert, PS McNamara… - Clinical …, 2020 - Elsevier
The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As
protective immunity does not exist in humans and the virus is capable of escaping innate …

COVID‐19 and toll‐like receptor 4 (TLR4): SARS‐CoV‐2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation

MM Aboudounya, RJ Heads - Mediators of inflammation, 2021 - Wiley Online Library
Causes of mortality from COVID‐19 include respiratory failure, heart failure, and
sepsis/multiorgan failure. TLR4 is an innate immune receptor on the cell surface that …

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

J Meng, G Xiao, J Zhang, X He, M Ou, J Bi… - Emerging microbes & …, 2020 - Taylor & Francis
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus
infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin …

[HTML][HTML] Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

C Wu, Y Liu, Y Yang, P Zhang, W Zhong… - … Pharmaceutica Sinica B, 2020 - Elsevier
SARS-CoV-2 has caused tens of thousands of infections and more than one thousand
deaths. There are currently no registered therapies for treating coronavirus infections …

Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of …

R Kreutz, EAEH Algharably, M Azizi… - Cardiovascular …, 2020 - academic.oup.com
Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of
mortality worldwide, and its importance is further emphasized in the context of the novel …

Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade

L Perico, A Benigni, G Remuzzi - Nephron, 2020 - karger.com
Here, we review the most recent findings on the effects of SARS-CoV-2 infection on kidney
diseases, including acute kidney injury, and examine the potential effects of ARBs on the …

ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities–role of gut microbiota dysbiosis

SD Viana, S Nunes, F Reis - Ageing research reviews, 2020 - Elsevier
Abstract Coronavirus disease 19 (COVID-19) is a pandemic condition caused by the new
coronavirus SARS-CoV-2. The typical symptoms are fever, cough, shortness of breath …

Pulmonary fibrosis as a result of acute lung inflammation: molecular mechanisms, relevant in vivo models, prognostic and therapeutic approaches

IA Savin, MA Zenkova, AV Sen'kova - International journal of molecular …, 2022 - mdpi.com
Pulmonary fibrosis is a chronic progressive lung disease that steadily leads to lung
architecture disruption and respiratory failure. The development of pulmonary fibrosis is …